Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10 Suppl
|
pubmed:dateCreated |
1990-6-14
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2409-10
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2334881-American Cancer Society,
pubmed-meshheading:2334881-Clinical Trials as Topic,
pubmed-meshheading:2334881-Drugs, Investigational,
pubmed-meshheading:2334881-Humans,
pubmed-meshheading:2334881-Insurance, Health, Reimbursement,
pubmed-meshheading:2334881-Patient Advocacy,
pubmed-meshheading:2334881-Patient Education as Topic,
pubmed-meshheading:2334881-United States
|
pubmed:year |
1990
|
pubmed:articleTitle |
Breakout II. Reimbursement concerns.
|
pubmed:publicationType |
Journal Article
|